Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by tillbillyon Nov 22, 2010 1:47pm

458 Views

Post# 17739984

RE: Closing price

Lots for sale at 23.5 no one willing to pay up.
I figure close at 22. Maybe after the rest of the test results shake out you will see conviction buyers.
Personaly I like the partial release and would prefer a slow rise...similar to the slow rise in the Gold price from 1260 to 1360.
Slow rises are more sustainable.
In any event it is nice to see a spec bet pay off .
GLTA

Bullboard Posts

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi